<DOC>
	<DOCNO>NCT02238366</DOCNO>
	<brief_summary>The purpose study collect parameter may help provide guidance Androgen Deprivation Therapy ( ADT ) drug renew physician satisfaction .</brief_summary>
	<brief_title>Study To Assess Renewal Of Treatment In Patients Recently Diagnosed With Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<criteria>Adult men , â‰¥18 year old , recently diagnose locally advanced metastatic prostate cancer schedule receive androgen deprivation therapy monotherapy concomitant adjuvant therapy association radiation therapy , 1 3 month GnRH analogue triptorelin formulation Expected survival &gt; 12 month . Patients provide write informed consent . Patients mentally fit complete questionnaire . Treatment investigational drug within last 3 month study entry plan participate study . Patients already treat GnRH analogue within last year . Patients hypersensitivity GnRH , GnRH analogue , triptorelin excipients . Patients contraindication accord SmPC .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>